205 related articles for article (PubMed ID: 26600051)
1. The Safety and Benefit of Statins in Liver Cirrhosis: a Review.
Souk K; Al-Badri M; Azar ST
Exp Clin Endocrinol Diabetes; 2015 Nov; 123(10):577-80. PubMed ID: 26600051
[TBL] [Abstract][Full Text] [Related]
2. Statin use in patients with cirrhosis: a retrospective cohort study.
Kumar S; Grace ND; Qamar AA
Dig Dis Sci; 2014 Aug; 59(8):1958-65. PubMed ID: 24838495
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of statins in the diseases of the liver.
Janicko M; Drazilova S; Pella D; Fedacko J; Jarcuska P
World J Gastroenterol; 2016 Jul; 22(27):6201-13. PubMed ID: 27468210
[TBL] [Abstract][Full Text] [Related]
4. Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation.
Patel SS; Guzman LA; Lin FP; Pence T; Reichman T; John B; Celi FS; Liptrap E; Bhati C; Siddiqui MS
Liver Transpl; 2018 Jul; 24(7):872-880. PubMed ID: 29624871
[TBL] [Abstract][Full Text] [Related]
5. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
Vargas JI; Arrese M; Shah VH; Arab JP
Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Sharpton SR; Loomba R
Hepatology; 2023 Dec; 78(6):1896-1906. PubMed ID: 37013380
[TBL] [Abstract][Full Text] [Related]
7. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.
Kaplan DE; Mehta R; Garcia-Tsao G; Albrecht J; Aytaman A; Baffy G; Bajaj J; Hernaez R; Hunt K; Ioannou G; Johnson K; Kanwal F; Lee TH; Monto A; Pandya P; Schaubel D; Taddei TH
Contemp Clin Trials; 2021 May; 104():106367. PubMed ID: 33771685
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.
Gu Y; Yang X; Liang H; Li D
BMC Gastroenterol; 2019 Dec; 19(1):231. PubMed ID: 31888534
[TBL] [Abstract][Full Text] [Related]
9. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy.
Muñoz AE; Pollarsky FD; Marino M; Cartier M; Vázquez H; Salgado P; Romero G
World J Gastroenterol; 2021 Jul; 27(28):4639-4652. PubMed ID: 34366626
[TBL] [Abstract][Full Text] [Related]
10. Safety of statin therapy in patients with preexisting liver disease.
Onofrei MD; Butler KL; Fuke DC; Miller HB
Pharmacotherapy; 2008 Apr; 28(4):522-9. PubMed ID: 18363535
[TBL] [Abstract][Full Text] [Related]
11. Statins and the liver.
Herrick C; Bahrainy S; Gill EA
Cardiol Clin; 2015 May; 33(2):257-65. PubMed ID: 25939298
[TBL] [Abstract][Full Text] [Related]
12. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
13. [Statins and cerebrovascular events].
Auer J; Berent R; Eber B
Herz; 2002 Dec; 27(8):765-71. PubMed ID: 12574894
[TBL] [Abstract][Full Text] [Related]
14. The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions.
Hilscher MB; Odell LJ; Myhre LJ; Prokop L; Talwalkar J
J Clin Pharm Ther; 2016 Dec; 41(6):587-591. PubMed ID: 27576303
[TBL] [Abstract][Full Text] [Related]
15. Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant.
Merkel M; Schneider C; Greinert R; Zipprich A; Ripoll C; Lammert F; Reichert MC
Hepatol Commun; 2021 Oct; 5(10):1755-1766. PubMed ID: 34558822
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis: can statins play a dual role?
Rajpara AN; Goldner R; Gaspari A
Dermatol Online J; 2010 Feb; 16(2):2. PubMed ID: 20178698
[TBL] [Abstract][Full Text] [Related]
17. Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry).
Dasari TW; Cohen DJ; Kleiman NS; Keyes MJ; Yen CH; Hanna EB; Saucedo JF
Am J Cardiol; 2014 Feb; 113(4):621-5. PubMed ID: 24342762
[TBL] [Abstract][Full Text] [Related]
18. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.
Kim RG; Loomba R; Prokop LJ; Singh S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1521-1530.e8. PubMed ID: 28479502
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia: management using optimal lipid-lowering therapy.
Ito MK
Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.
McAlister FA; Majumdar SR; Lin M; Bakal J; Fradette M; Anderson T
Can J Cardiol; 2014 Dec; 30(12):1627-32. PubMed ID: 25307535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
